Moderna disclosed in a financial filing this week that it received another $300 million in U.S. government funding for coronavirus vaccine development in March even as the company hoarded its technology from the world.
The Massachusetts-based pharmaceutical giant Moderna disclosed in a financial filing this week that it received another $300 million in U.S. government funding for coronavirus vaccine development in March even as the company hoarded its technology from the world — and attempted toto the U.S.
“The maximum award from [the Biomedical Advanced Research and Development Authority], inclusive of the 2020, 2021, and 2022 amendments, was approximately $1.7 billion,” the filing reads. “All contract options have been exercised. As of March 31, 2022, the remaining available funding, net of revenue earned was $378 million.”
Zain Rizvi, a researcher with Public Citizen’s Access to Medicines program, called the sum of public funding that has flowed to Moderna “staggering.” In a new financial filing, Moderna discloses receiving another $300M from the U.S. government in March 2022 for vaccine development. Excluding dose purchases and NIH contributions, public support for mRNA-1273 R&D now stands at a staggering $1.7 billion dollars .